Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Avanos Medical, Inc. (NYSE: AVNS), a medical technology company headquartered in Alpharetta, Georgia. Through these filings, investors can review how Avanos reports its financial performance, strategic actions and governance matters related to its Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R) segments.
Avanos uses current reports on Form 8-K to disclose material events. These include earnings releases that present quarterly and year-to-date results, segment net sales and operating income, and non-GAAP measures such as adjusted operating income, adjusted net income, adjusted diluted earnings per share, adjusted EBITDA and free cash flow. The company explains in these filings which items are excluded from non-GAAP measures, such as acquisition and integration charges, restructuring and transformation expenses, EU Medical Device Regulation compliance costs, amortization of acquisition-related intangibles, impairments, certain tax effects and currency impacts.
Form 8-K filings also document strategic portfolio moves and organizational changes. Avanos has furnished press releases describing the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, the agreement for WRS Group to acquire its US Game Ready orthopedic rental business and the acquisition of Nexus Medical, LLC. Other 8-K items cover executive appointments, board changes and an organizational restructuring that eliminated certain senior roles, along with details of severance and equity treatment under the company’s established plans.
Stock Titan enhances these regulatory disclosures with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of earnings releases, transaction announcements and governance updates. Real-time ingestion of EDGAR data means new Avanos Forms 8-K and other SEC documents appear promptly, while AI-generated overviews and tagging make it easier to locate information on segment performance, non-GAAP reconciliations and executive compensation arrangements.
Avanos Medical, Inc. filed an 8-K to announce results for the three and nine months ended September 30, 2025. The company reported its results of operations and financial condition for these periods.
The announcement was provided via a press release furnished as Exhibit 99.1. The company stated the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under the Exchange Act.
The Vanguard Group filed Amendment No. 12 to Schedule 13G on Avanos Medical (AVNS), reporting beneficial ownership of 3,425,214 shares of common stock, representing 7.38% of the class as of 09/30/2025. Vanguard reports 0 shares with sole voting power and 371,596 with shared voting power. It has 2,979,548 shares with sole dispositive power and 445,666 with shared dispositive power.
Vanguard is identified as an investment adviser and certifies the holdings were acquired and are held in the ordinary course of business and not to change or influence control. Dividends and sale proceeds are for Vanguard’s clients, including registered investment companies and other managed accounts, with no single client over 5%.
Avanos Medical (AVNS) is eliminating its Chief Commercial Officer and General Counsel positions as part of a broader restructuring, effective December 1, 2025. The company notified Senior Vice Presidents Kerr Holbrook (CCO) and Mojirade James (General Counsel and Secretary) of their employment termination tied to the role eliminations, with responsibilities to be reallocated across other employees.
Under the Severance Pay Plan, Avanos will pay $1,535,417 to Mr. Holbrook and $1,425,665 to Ms. James, and cover 100% of COBRA premiums for 12 months. Unvested time-based RSUs will vest pro rata through the termination date, PSUs will vest at period end based on actual performance, and stock options will remain exercisable for five years (or earlier expiration). Each executive will receive a prorated 2025 bonus at target. These benefits are conditioned on signed separation agreements, a general release, and continued compliance with confidentiality and non-solicitation obligations.
Dimensional Fund Advisors LP reports ownership of 2,352,634 shares of Avanos Medical Inc common stock, representing 5.1% of the outstanding class. The filing shows Dimensional has sole voting power over 2,282,916 shares and sole dispositive power over 2,352,634 shares, while disclaiming beneficial ownership because the shares are owned by client Funds. The statement clarifies these holdings are managed in an advisory capacity for multiple commingled funds and separate accounts and are held in the ordinary course of business without intent to influence control.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A disclosing beneficial ownership of 4,713,494 shares of Avanos Medical, Inc. common stock, representing 10.2% of the class as of 09/30/2025. The filer reports sole voting power for 4,683,148 shares and sole dispositive power for 4,713,494 shares. The filing notes that T. Rowe Price Small-Cap Value Fund holds 2,546,726 shares (about 5.5%) as part of its managed portfolio. The statement affirms the securities are held in the ordinary course of business and not for the purpose of changing control.
Avanos Medical, Inc. reported that on September 15, 2025 it acquired Nexus Medical, LLC. The company disclosed this event through a current report and referenced a press release that provides more information about the transaction.
The press release announcing the acquisition is attached as Exhibit 99.1 and is furnished under Regulation FD, meaning it is intended to share information broadly with the market but is not treated as filed for liability purposes under certain securities laws. Avanos’ common stock continues to trade on the New York Stock Exchange under the symbol AVNS.
John Joseph Hurley, Principal Accounting Officer of Avanos Medical, Inc. (AVNS), reported a Form 4 disclosing a tax-withholding sale tied to vested restricted stock units. On 09/05/2025 the filing shows 345 shares were disposed of at $12.66 per share under transaction code F(1). The filing explains these shares were surrendered to the issuer to satisfy tax withholding on time-based restricted share units awarded on 09/05/2024. After the transaction, Hurley beneficially owns 11,364 shares directly. The Form 4 was signed by an attorney-in-fact on 09/09/2025.
Scott M. Galovan, SVP and Chief Financial Officer of Avanos Medical, reported beneficial ownership of 111,009 shares of common stock on Form 3 filed for the 08/01/2025 event. Of those shares, 80,718 are unvested time-based restricted share units that vest on scheduled dates through August 1, 2028. The filing also lists employee stock options totaling 26,582 underlying shares with varying exercise prices and vesting/exercise dates.
Gary Blackford, a director of Avanos Medical, Inc. (AVNS), reported purchases of a total of 60,000 shares on 08/13/2025 in two grouped transactions: 20,000 shares acquired at a weighted-average price of $10.975 and 40,000 shares acquired at a weighted-average price of $10.995.
Following these transactions the filing shows 91,593 shares beneficially owned directly and 40,000 shares held indirectly in trusts for immediate family members (the reporting person is co-trustee and disclaims beneficial ownership except to the extent of pecuniary interest). The Form 4 was signed by an attorney-in-fact on 08/15/2025.